

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



遠大醫藥集團

GRAND PHARMACEUTICAL GROUP

Grand Pharmaceutical Group Limited

遠大醫藥健康控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 00512)

PROPOSED ADOPTION OF NEW BYE-LAWS

This announcement is made by Grand Pharmaceutical Group Limited (the “**Company**”) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board of directors (the “**Board**”) of the Company proposes to make certain amendments to the bye-laws of the Company currently in force (the “**Existing Bye-laws**”), (i) to in line with the relevant requirements of the Listing Rules, including the core shareholder protection standards set out in Appendix 3 to the Listing Rules, and the applicable laws of Bermuda; and (ii) making other housekeeping amendments, including consequential amendments in line with the above amendments to the Existing Bye-laws (collectively, the “**Proposed Amendments**”).

The Board proposes to adopt a new set of bye-laws incorporating and consolidating the Proposed Amendments in substitution for, and to the exclusion of, the Existing Bye-laws, which will be subject to the approval of the shareholders of the Company (“**Shareholders**”) by way of a special resolution to be proposed at the annual general meeting of the Company to be held on 2 June 2023 (the “**AGM**”).

A circular containing, among other things, details of the Proposed Amendments together with a notice convening the AGM will be despatched to the Shareholders in due course.

By Order of the Board
Grand Pharmaceutical Group Limited
Dr. Tang Weikun
Chairman

Hong Kong, 27 April 2023

As at the date of this announcement, the Board comprises four executive directors, namely, Dr. Tang Weikun, Dr. Shao Yan, Dr. Niu Zhanqi and Dr. Shi Lin, and three independent non-executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Pei Geng and Mr. Hu Yebi.

** For identification purpose only*